Bachem renews Goserelin agreement with AZ
Will continue supply for the next seven years
Swiss biochemicals supplier Bachem has renewed an agreement with AstraZeneca for the supply of Goserelin for the next seven years.
Bachem has been supplying Goserelin to AstraZeneca for more than 20 years.
AstraZeneca uses the product in Zoladex, its injectable gonadotropin releasing hormone super-agonist.
With headquarters in Bubendorf and affiliates in Europe and the US, Bachem specialises in the process development and manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients, as well as innovative biochemicals for research purposes.
